All In Biotech

Drug Trial Radar · NCT01936649

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)

Last checked: Nov 19, 2026Latest source record: Dec 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

63

Actual

Start

Aug 2013

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
H2O Clinical LLC; Quintiles, Inc.
First posted
Sep 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.

Conditions

  • Heart Failure (HF)
  • Ventricular Dysfunction, Left

Interventions

  • AdreView (Iobenguane I 123 Injection)Drug

    AdreView 10 mCi as a single i.v administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Assess Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake in Heart Failure (HF) Participants on Planar Imaging at 3 Hours 50 Minutes Following I.V. Injection of AdreView (Iobenguane I 123 Injection)Time frame: 3 Hours 50 Minutes post administration of 2 dosing within an interval of 5 to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.